Article

C-reactive protein (CRP) promoter polymorphisms influence circulating CRP levels in a genome-wide association study of African Americans

Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Human Molecular Genetics (Impact Factor: 6.68). 04/2012; 21(13):3063-72. DOI: 10.1093/hmg/dds133
Source: PubMed

ABSTRACT C-reactive protein (CRP) is an acute phase reactant protein produced primarily by the liver. Circulating CRP levels are influenced by genetic and non-genetic factors, including infection and obesity. Genome-wide association studies (GWAS) provide an unbiased approach towards identifying loci influencing CRP levels. None of the six GWAS for CRP levels has been conducted in an African ancestry population. The present study aims to: (i) identify genetic variants that influence serum CRP in African Americans (AA) using a genome-wide association approach and replicate these findings in West Africans (WA), (ii) assess transferability of major signals for CRP reported in European ancestry populations (EA) to AA and (iii) use the weak linkage disequilibrium (LD) structure characteristic of African ancestry populations to fine-map the previously reported CRP locus. The discovery cohort comprised 837 unrelated AA, with the replication of significant single-nucleotide polymorphisms (SNPs) assessed in 486 WA. The association analysis was conducted with 2 366 856 genotyped and imputed SNPs under an additive genetic model with adjustment for appropriate covariates. Genome-wide and replication significances were set at P < 5 × 10(-8) and P < 0.05, respectively. Ten SNPs in (CRP pseudogene-1) CRPP1 and CRP genes were associated with serum CRP (P = 2.4 × 10(-09) to 4.3 × 10(-11)). All but one of the top-scoring SNPs associated with CRP in AA were successfully replicated in WA. CRP signals previously identified in EA samples were transferable to AAs, and we were able to fine-map this signal, reducing the region of interest from the 25 kb of LD around the locus in the HapMap CEU sample to only 8 kb in our AA sample.

Download full-text

Full-text

Available from: Olufemi Fasanmade, Aug 27, 2015
0 Followers
 · 
258 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die Durchführung einer individualisierten Therapie chronisch-entzündlicher Darmerkrankungen bedarf einer intensiven Überwachung, insbesondere bei Patienten mit Risikoprofil für schwerwiegende Verläufe sowie nachweisbarer Entzündung. Eine rein klinische Evaluation hat eine Reihe von Limitationen, so dass weitere Instrumente zur Erfassung der Entzündung notwendig sind. Zu den nichtinvasiven Maßnahmen der Therapieüberwachung gehören insbesondere das CRP bei Morbus Crohn sowie fäkale Stuhlmarker wie Calprotectin für Morbus Crohn und Colitis ulcerosa, die teilweise eine sehr gute Korrelation zur endoskopischen Aktivität aufweisen. Zudem korrelieren Veränderungen dieser Parameter mit einem Therapieansprechen und weisen auf eine erhöhte Rezidivgefahr hin. Die Endoskopie bleibt allerdings weiterhin eine wichtige Methode in der Therapieüberwachung, die gerade bei wichtigen Therapieentscheidungen herangezogen werden muss. Nach Therapieeskalation oder auch -deeskalation kann man sich in der Beurteilung der Effektivität oft auf die Überprüfung von CRP und/oder fäkales Calprotectin beschränken und somit erneute endoskopische Untersuchungen vermeiden. Weniger gut evaluiert in der Therapieüberwachung sind Ultraschall, MRT und Kapselendoskopie, so dass diese eher in Einzelfällen herangezogen werden. Somit stehen insbesondere mit CRP und Calprotectin neben der Endoskopie wichtige Hilfsmittel zur Verfügung, um die Therapie chronisch-entzündlicher Darmerkrankungen nachhaltig zu optimieren.
    Der Gastroenterologe 08/2014; 8(3). DOI:10.1007/s11377-012-0723-5
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: C-reactive protein (CRP) is a systemic inflammation marker that predicts future cardiovascular risk. CRP levels are higher in African Americans and Hispanic Americans than in European Americans, but the genetic determinants of CRP in these admixed United States minority populations are largely unknown. We performed genome-wide association studies (GWASs) of 8,280 African American (AA) and 3,548 Hispanic American (HA) postmenopausal women from the Women's Health Initiative SNP Health Association Resource. We discovered and validated a CRP-associated variant of triggering receptors expressed by myeloid cells 2 (TREM2) in chromosomal region 6p21 (p = 10(-10)). The TREM2 variant associated with higher CRP is common in Africa but rare in other ancestral populations. In AA women, the CRP region in 1q23 contained a strong admixture association signal (p = 10(-17)), which appears to be related to several independent CRP-associated alleles; the strongest of these is present only in African ancestral populations and is associated with higher CRP. Of the other genomic loci previously associated with CRP through GWASs of European populations, most loci (LEPR, IL1RN, IL6R, GCKR, NLRP3, HNF1A, HNF4A, and APOC1) showed consistent patterns of association with CRP in AA and HA women. In summary, we have identified a common TREM2 variant associated with CRP in United States minority populations. The genetic architecture underlying the CRP phenotype in AA women is complex and involves genetic variants shared across populations, as well as variants specific to populations of African descent.
    The American Journal of Human Genetics 08/2012; 91(3):502-12. DOI:10.1016/j.ajhg.2012.07.023 · 10.99 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Health disparities are an immense challenge to American society. Clinical and Translational Science Awards (CTSAs) housed within the National Center for Advancing Translational Science (NCATS) are designed to accelerate the translation of experimental findings into clinically meaningful practices and bring new therapies to the doorsteps of all patients. Research Centers at Minority Institutions (RCMI) program at the National Institute on Minority Health and Health Disparities (NIMHD) are designed to build capacity for biomedical research and training at minority serving institutions. The CTSA created a mechanism fostering formal collaborations between research intensive universities and minority serving institutions (MSI) supported by the RCMI program. These consortium-level collaborations activate unique translational research approaches to reduce health disparities with credence to each academic institutions history and unique characteristics. Five formal partnerships between research intensive universities and MSI have formed as a result of the CTSA and RCMI programs. These partnerships present a multifocal approach; shifting cultural change and consciousness toward addressing health disparities, and training the next generation of minority scientists. This collaborative model is based on the respective strengths and contributions of the partnering institutions, allowing bidirectional interchange and leveraging NIH and institutional investments providing measurable benchmarks toward the elimination of health disparities.
    Clinical and Translational Science 10/2013; 6(6). DOI:10.1111/cts.12118 · 2.11 Impact Factor
Show more